We provide alerts on penny stocks, due diligence on undervalued micro cap stocks, and tools & tips on trading and investing Breakout stock patterns Unusual penny stocks activity Penny Stocks being promoted Breaking News Volume & Momentum Alerts Initial Public Offerings Disclosure & Disclaimer The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. http://www.rockastocks.com/disclaimer.html --------------------------------------------------------------------------------
I am a mid-westerner and computer science grad helping to launch a start-up medical service company. I've worked on medical intake including XML delivery, medical instrumentation imaging, tissue ablation micro-imaging and MEMs device modeling.
I know biotech, which I prefer to call biopharmaceuticals. Period. I love investing and I write when I can!
I am an American trader and a Vanderbilt University alumnus currently living in San Francisco. I'm mostly interested in income investing using dividends, preferred stocks and other debt instruments, and pair trading.
I fundamentally analyze every business from the top down.
In my personal life, I have a strong Jewish faith and enjoy playing Scrabble and entrepreneurship.
I am a personal investor and an attorney. I have extensive experience in the consumer credit arena as well as commercial real estate as an investor and a lender. I co-manage a commercial, hard money mortgage fund and also have experience with the Food, Drug & Cosmetic Act.
I research early (micro cap) and mid phase publicly traded companies in the Biotechnology and Medical Device sectors that are harder to at times find information on for investors. I believe that these companies, although potentially more volatile than their larger cap retail counterparts, hold great value. With a clear understanding of where their product is positioned in the market, the capitalization and the team, these smaller companies can hold incredible value over the long term.
I have a varied background in both business and in the technical sector. Currently, I also am a co founder of BCN Biosciences in Pasadena CA, a privately held biotechnology company in addition to holding a research faculty position at the University of California Los Angeles Department of Radiation Oncology.
I have been an independent investor and trader in the Forex, Stock Market, and Commodity markets for 10 years. I also serve as the managing director of a charitable fund.
Follow me on Twitter @spollack10
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
25 years with Wall Street firms then running a "long bias" hedge fund since 1997. Focus on equities and preferred stocks.
Very diverse portfolio partially hedged with short S&P 500 index calls. Usually 30-60% net long.
Edward Schneider is a managing director of Quan Management LLC. Mr. Schneider has over 25 years of investment experience, including 18 years managing technology funds in both quoted equities and venture capital. Mr. Schneider holds a CFA designation, an MBA from Thunderbird and a BA from Emory University.
#11 Ranked Blogger for 2014 from over 4,100 bloggers - TipRanks
Quan Technology Fund - #1 Ranked Fund in Europe for 2014 with a net return of +71% - Preqin Fund Ranking
Steven Bulwa is an investment analyst with a focus on new developments in science, technology and medicine and the companies poised to benefit. He has contributed to TheStreet.com, Realmoney.com and SeekingAlpha.com, BusinessInsider.com, Mediaite.com and HuffingtonPost.com among others. Steven has actively followed developments in technology for over 20 years, working with a scientific advisory board to validate potential investments. Early in his career, as a musician and recording engineer, Steven recognized the importance of the shift from analog to digital recording. This inspired his first stock investment in a company providing hardware and software solutions to television news providers converting to a digital video environment. The success of this investment inspired Steven to continue to delve into yet-to-be recognized investment opportunities in technology. While writing for thestreet.com in 2006, Steven was one of the first analysts to identify the explosive investment opportunity of 3D Printing. At the time he wrote articles about Stratasys(SSYS) and 3D Systems(DDD). Steven's picks like Nuvasive(NUVA) were also featured on Jim Cramer's Mad Money on CNBC. He has also acted as a consultant to companies looking to acquire new technologies including nanotechnology.
A practical investor, Steven also called the demise of the housing and mortgage markets after listening to one of Ben Bernanke’s early testimonies while simultaneously learning of Bank of America’s efforts to proactively renegotiate troubled home loans. In our capitalist economy, companies only renegotiate out of desperation, trouble was obviously coming!
Technology now evolves so rapidly that there are always great new technology companies with tremendous growth potential to invest in. Big cap tech's strongest growth is past, Steve wants to help you invest in tomorrow’s Apple,Google, or Microsoft.
Sol Palha is the head financial analyst at Tactical Investor. He is a self-taught Student of the Markets, having widely read conventional and non-conventional texts on all aspects of technical analysis, Mass Psychology and philosophy (as he believes it can be quite useful in terms of market analysis). He has been studying the markets for over 18 years. He combines mass psychology, technical analysis and a new field of study that he has pioneered, Esoteric Cycle Analysis to determine market tops and bottoms. Mass Psychology and Technical analysis is a deadly combination, and has enabled us to accurately determine Market tops and bottoms in advance of the actual event. One should not confuse topping and bottoming action, with trying to predict the actual top or bottom------- An endeavor best left to fools with plenty of time on their hands and an inordinate capacity to deal with pain and failure.
Tom Aspray, professional trader and analyst was originally trained as a biochemist but began using his computer expertise to analyze the financial markets in the early 1980s. Mr. Aspray has written widely on technical analysis and has given over 60 presentations around the world. Many of the technical indicators that Mr. Aspray wrote about in the 1980s, such as the MACD, have since gained worldwide acceptance.
Tom is regular contributor to Forbes where he writes a regular Week Ahead column. His expertise as a technical analyst has been acknowledged by the WSJ as well as some of the best known technical analysts.
Oil & Gas 360® is a one-stop source of news and information from the professionals at EnerCom, Inc. The website is dedicated to all things oil and gas: people, technologies, transactions, trends, and macro-economic analysis that impacts commodity prices.
Our goal with Oil & Gas 360® is to be a trusted source of information and analysis for portfolio managers, equity research analysts, private equity capital providers, private investors, oil and gas executives and professionals, and government officials involved in the oil and gas industry.
We are an independent equity service dedicated to increasing the visibility of public and private companies worldwide. We specialize in healthcare, pharma/biotech, telecommunications, energy, and technology markets, and seek out companies demonstrating:
Solid growth prospects
Well-designed operating and growth strategies
An experienced and proven management team
Command of a niche position in a large and expanding market
A unique or innovative position or technology
Crystal Research Associates has been recognized on CNBC, CNBC Europe, Fox Business, Bloomberg, Bloomberg Radio, and CBS, among other networks, and in the International Herald Tribune, the South Florida Business Journal, MedAdNews, the New York Times, Forbes, BusinessWeek, PharmaLive, and CBS MarketWatch.
CEO and Senior Analyst Jeffrey Kraws has also been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked several times as the number one stock performance analyst in the world for pharmaceuticals from Starmine and for estimates from Zacks. Additionally, he has been 5-Star Ranked for top biotechnology stock performance by Starmine.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
The stock market is an incredibly interesting and dynamic puzzle that continues to draw me in like a game of chess where every few moves your opponent changes and parts of the board are obscured.
The investment models I design are typically used by family offices, hedge funds, brokerages and single investors. If you are interested in developing a certain model and want to throw a few ideas around, you are most welcome to contact me without feeling pressure or obligation.
My other passion is volunteering with the deaf. My wife and I moved to Malawi Africa from 2014 to 2016 where we learned Malawi Sign Language.
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future.
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.